Please login to the form below

Not currently logged in
Email:
Password:

Regeneron taps Pfizer for CFO

Robert Landry succeeds Murray Goldberg

Robert Landry, Regeneron Former Pfizer senior VP Robert Landry has joined Regeneron as senior VP, finance, and will later take over as chief financial officer.

Landry (pictured) was most recently senior VP and treasurer at Pfizer having joined the company in 2009 as senior VP, finance.

Prior to his time at Pfizer, he was treasurer at Wyeth, which was acquired by Pfizer in 2009. He was also previously chief financial officer for Wyeth's Australian and New Zealand affiliates.

Landry assumes the role of senior VP at Regeneron immediately and will succeed Murray Goldberg as chief financial officer on October 1 when Goldberg steps after 18 years with Regeneron.

Meanwhile, Goldberg will transition to a new role as senior VP, administration, in anticipation of his full retirement at the end of 2014.

Reporting to CEO Dr Leonard Schleifer, Landry will have responsibility for all financial functions, including treasury, financial planning, tax, and internal audit.

"We are extremely fortunate that Murray will stay at Regeneron through 2014 to help us with the transition to a new chief financial officer," said Dr Schleifer.

"Bob Landry brings with him a breadth of domestic and international financial expertise at Pfizer and Wyeth. We look forward to the valuable perspective he will bring, as we continue to expand our operations in the US and globally."

17th September 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics